I have owned PLI since the heady days of the last $2.00 share price. I don't need to be told about the secondary business units or the partnerships since none are particularly new and the only fundamental change since the share was at 20 cents is the Octapharma. 

Ultimately sales have increased in the last 18 months to a stage where, at least temporarily, the company has the potential to make a quarterly profit. The company has to build on those sales and increase them just to justify the current market cap. This is not 2008, the market is not going to randomly throw money at new/existing parmaceutical companies. Sales matter and earnings will be the deciding factor as to whether the market cap will continue to climb.